Start Free Trial

Controlling metabolic fluxes for better human haematopoietic stem cell function

Horizon Europe Guarantee · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Active
Status

Opportunity Overview

Hematopoietic stem cells (HSCs) ex vivo culture is a fundamental step for HSC-based Gene Therapy (GT), the only curative treatment for more than 10 distinct monogenic diseases worldwide. However, a major clinical challenge for HSC GT arises from the loss of HSC function during ex vivo culture, posing a high risk of delayed or failed blood recovery in patients. Recent work from Laurenti laboratory has demonstrated that more than 50% of functional HSCs are lost within the early adaptation to ex vivo culture with significant transcriptional remodelling in genes linked to metabolism. Metabolic switches are known key regulators of HSC function in vivo. Therefore, the central hypotheses of this proposal are that i) metabolic switches contribute to the early loss of human HSCs regenerative capacity during ex vivo culture, ii) targeting metabolic switches pharmacologically can improve HSC function ex vivo. This proposal will first generate a kinetically resolved map of metabolomic switches occurring during human HSC ex vivo adaptation. For this, I will integrate metabolomic analysis on highly purified human HSCs cultured in preclinical GT conditions with scRNA-seq data. My preliminary work, using computational methods on time-course scRNA-seq and functional assays with small molecule inhibitors, has identified purinergic metabolism fluxes as dynamically changed and pharmacologically targetable during HSC ex vivo adaptation. Therefore, in my second aim, I will screen the effects of pharmacological inhibition of key purinergic enzymes to determine how the purinergic metabolic switch: i) regulates HSC function ex vivo and ii) affects HSC regeneration using a preclinical model of HSC GT. This project will generate new insights into the interplay between stem cell metabolism, stress and regeneration. In addition, it will identify new preclinical strategies to improve HSC function ex vivo, with direct relevance to HSC GT and other clinical applications requiring HSC culture.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHorizon Europe Guarantee
CountryUnited Kingdom
CategoryBiotechnology
Response dueNot specified / rolling
StatusActive - open for responses
Official sourceView original notice

Related Opportunities in United Kingdom

University of Strathclyde and Anderson Bell Christie Limited KTP 21_22 R2
Combating highly pathogenic avian influenza: Novel vaccination strategies using recombinant live avian viral vaccine vectors. THIS GRANT IS A SUPPLEM
Nanophotonic Artificial Tongue for Disease State Classification
Extracellular Vesicles in cell-cell communication for health across the life course
Developing multiplex genome editing in the chicken using serial surrogate host mating
Determination of the high resolution structure of the polypeptide chain in amyloid fibrils
Generation of high-value sesquiterpene products from renewable feedstocks using lignin-degrading microbes
Removal of Endocrine Disruptor Bisphenol A from Water

See every United Kingdom Biotechnology opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →